ND-003 / Shenzhen Xinyue - LARVOL DELTA

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers (clinicaltrials.gov) - P1 | N=96 | Enrolling by invitation | Sponsor: Shenzhen NewDEL Biotech, Co., Ltd | Trial completion date: Jun 2026 ➔ Dec 2028 | Trial primary completion date: Dec 2025 ➔ Jun 2028

Trial completion date • Trial primary completion date • Oncology • Solid Tumor • NTRK • RET

A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults (clinicaltrials.gov) - P1 | N=104 | Enrolling by invitation | Sponsor: Shenzhen NewDEL Biotech, Co., Ltd | Not yet recruiting ➔ Enrolling by invitation

Enrollment open

A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults (clinicaltrials.gov) - P1 | N=104 | Not yet recruiting | Sponsor: Shenzhen NewDEL Biotech, Co., Ltd

New P1 trial

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers (clinicaltrials.gov) - P1 | N=96 | Enrolling by invitation | Sponsor: Shenzhen NewDEL Biotech, Co., Ltd | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Metastases • Oncology • Solid Tumor

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers (clinicaltrials.gov) - P1 | N=96 | Not yet recruiting | Sponsor: Shenzhen NewDEL Biotech, Co., Ltd

New P1 trial • Oncology • Solid Tumor